73 - Syphilis in the US: It’s Unrelenting

Thursday, October 17, 2024

1:45 PM – 3:00 PM US PT

Location: Concourse 152

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Emily Erbelding, MD (she/her/hers)

Director, Division of Microbiology and Infectious Disease NIAID
National Institutes of Health
Rockville, MD, United States
Colleen Kelley, MD, MPH (she/her/hers)

Associate Professor of Medicine
Emory University
Decatur, GA, United States

Faculty(s)

Kevin O'Callaghan, MB BCh BAO (he/him/his)

Medical officer/epidemiologist
Division of STD Prevention
Centers for Disease Control and Prevention
Powder Springs, GA, United States
Chase Cannon, MD MPH (he/him/his)

Assistant Professor of Medicine
University of Washington
Seattle, WA, United States
Khalil Ghanem, MD, PhD (he/him/his)

Professor
Division of Infectious Diseases, Department of Medicine
Johns Hopkins University
Baltimore, MD, United States

Disclosure(s):

Emily Erbelding, MD: No financial relationships to disclose

Colleen F. Kelley, MD, MPH: Gilead Sciences: Grant/Research Support (Ongoing); Humanigen, Inc: Grant/Research Support (Terminated); Moderna, Inc.: Grant/Research Support (Terminated); Novavax, Inc.: Grant/Research Support (Terminated); ViiV Healtcare: Grant/Research Support (Ongoing)

Kevin P. O'Callaghan, MB BCh BAO: No financial relationships to disclose

Chase Cannon, MD MPH: No financial relationships to disclose

Khalil G. Ghanem, MD, PhD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe public health impact of point-of-care syphilis testing in syphilis outbreaks;
Describe implementation of Doxy-PEP and its impact;
identify clinical challenges in syphilis management.

Presentations:

1:45 PM – 2:10 PM US PT

Bridging the Treatment Gap: Estimating the Impact of Widespread Syphilis Point-of-Care Testing
Speaker: Kevin P. O'Callaghan, MB BCh BAO (he/him/his) – Centers for Disease Control and Prevention
2:10 PM – 2:35 PM US PT

Can Doxy-PEP Implementation Reverse Syphilis Trends?
Speaker: Chase Cannon, MD MPH (he/him/his) – University of Washington
2:35 PM – 3:00 PM US PT

Clinical Conundrums in Syphilis Management
Speaker: Khalil G. Ghanem, MD, PhD (he/him/his) – Johns Hopkins University